Two-headed molecule clears lymphoma tumors in mice

A lymphoma tumor disappeared from the mice in 11 days. Stanford Medicine researchers treated animals twice a day with TCIP3, a two-headed molecule designed to turn the cancer’s own growth driver against it. The treated tumors were completely gone, while those in control animals remained.

The target is BCL6, a protein often implicated in diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma. In healthy immune cells, BCL6 temporarily silences genes that halt growth or trigger programmed cell death, also called apoptosis. In lymphoma, it can remain permanently active, allowing cancer cells to proliferate unchecked.

TCIP3 works by chemically induced proximity: one side binds BCL6, while the other binds P300 or CBP. Those proteins add acetyl marks to BCL6 and to histones, the structures that package DNA. The marks disable BCL6’s gene-silencing function and open access to genes that activate cell death. X-ray structural studies showed that the linked proteins also formed additional contacts, acting like a “molecular glue” and strengthening the effect.

The Stanford team found that TCIP3 killed lab-grown lymphoma cells at very low concentrations. In treated mice, there were no obvious signs of toxicity and blood tests showed no spike in inflammatory signals. But the molecule also eliminated germinal centers, clusters of rapidly dividing immune cells that rely heavily on BCL6. Because those cells are implicated in rheumatoid arthritis and myasthenia gravis, the researchers see a possible future application beyond cancer.

So what changes concretely? The approach offers a way to use a cancer-causing protein as the handle for activating cell death, rather than merely blocking or degrading it. For patients, that remains a research possibility, not a treatment: TCIP3 needs further chemical refinement and testing in additional animal species before human trials can be considered.